VP
venBio Partners Portfolio holdings
AUM
$115M
This Quarter Return
+137.87%
1 Year Return
-33.99%
3 Year Return
+221.07%
5 Year Return
+224.54%
10 Year Return
–
AUM
$667M
AUM Growth
+$667M
(+89%)
Cap. Flow
-$7.99M
Cap. Flow
% of AUM
-1.2%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
1
Reduced
–
Closed
1
Top Buys
| 1 |
Pharvaris
PHVS
|
$18.4M |
Top Sells
| 1 |
Ventyx Biosciences
VTYX
|
$26.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RYZB
1
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $321M | 48.06% | 5,158,162 | – | – |
|
2
ALX Oncology
ALXO
$62.7M
| $144M | 21.65% | 9,699,925 | – | – |
|
|
3
Pharvaris
PHVS
$1.39B
| $138M | 20.68% | 4,919,504 +654,832 | +15% | +$18.4M |
|
4
Harmony Biosciences
HRMY
$2.12B
| $33.4M | 5.01% | 1,035,396 | – | – |
|
|
SLRN
5
DELISTED
ACELYRIN
SLRN
| $28.7M | 4.31% | 3,852,470 | – | – |
|
|
ELEV
6
DELISTED
Elevation Oncology
ELEV
| $1.56M | 0.23% | 2,914,255 | – | – |
|
|
IMPL
7
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
| $341K | 0.05% | 2,759,791 | – | – |
|
|
8
Ventyx Biosciences
VTYX
$171M
| – | – | -758,800 | Closed | -$26.4M |
|